PBAC's latest decision on Macitentan with tadalafil: Recommended with restriction (2024). Considered for Continuing treatment of pulmonary arterial hypertension (PAH) in patients who are on stable doses of macitentan and tadalafil as combination therapy.
PBAC outcome
Recommended with restriction
Authority Required
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
1
first 2024
Submissions
1
2024 → 2024
Eligible population
Adult patients with WHO functional class III and IV pulmonary arterial hypertension who are on stable, separate doses of macitentan 10 mg and tadalafil 40 mg (20 mg x 2).
Therapy area
Respiratory
Line of therapy
Not applicable
Evidence base
Cost-minimisation
Primary endpoint
Cost-minimisation
Comparator
macitentan 10 mg tablet with 2 x 20 mg tadalafil tablets as dual therapy or with a prostanoid as triple therapy
Economic model
Cost-minimisation
ICER note
Cost-minimisation analysis; no ICER calculated by design.